Warnock Julia K, Morris David W
University of Oklahoma Health Sciences Center, Tulsa, Oklahoma 74135, USA.
Am J Clin Dermatol. 2003;4(1):21-30. doi: 10.2165/00128071-200304010-00003.
Of all the psychotropic medications currently available, the mood-stabilizing agents have the highest incidence of severe and life-threatening adverse cutaneous drug reactions (ACDRs). An exanthematous eruption in a patient treated with a mood-stabilizing agent should be viewed as possibly being the initial symptom of a severe and life-threatening ACDR, such as a hypersensitivity reaction, Stevens-Johnson syndrome, or toxic epidermal necrolysis. The combination of mood-stabilizing agents may increase the risk of such reactions. The mood-stabilizing agents addressed in this article are carbamazepine, lithium carbonate, valproic acid, topiramate, lamotrigine, gabapentin, and oxcarbazepine. Prior to the initiation of a mood stabilizer, the potential benefits, risks, and adverse effects should be communicated to the patient. If possible, slow dose escalation should be attempted by the physician. Patients should also be advised to seek medical attention if they suspect a drug-induced skin reaction. If the physician suspects a severe ACDR, the offending agent should be removed immediately.
在目前可用的所有精神药物中,心境稳定剂引发严重及危及生命的药物不良反应(ACDR)的发生率最高。使用心境稳定剂治疗的患者出现皮疹应被视为可能是严重及危及生命的ACDR的初始症状,如过敏反应、史蒂文斯-约翰逊综合征或中毒性表皮坏死松解症。联合使用心境稳定剂可能会增加此类反应的风险。本文讨论的心境稳定剂有卡马西平、碳酸锂、丙戊酸、托吡酯、拉莫三嗪、加巴喷丁和奥卡西平。在开始使用心境稳定剂之前向患者说明潜在的益处、风险和不良反应。如果可能,医生应尝试缓慢增加剂量。还应建议患者如果怀疑有药物引起的皮肤反应应寻求医疗帮助。如果医生怀疑是严重的ACDR,应立即停用引起问题的药物。